TenNor Therapeutics (Suzhou) Limited

М੽Ԛ哦丹诺医药(苏州)股份有限公司

06872.HK

Near-commercial stage biotechnology company developing therapies for bacterial infections and gut bacterial metabolism-related diseases, targeting antimicrobial resistance, using its multi-targeting conjugate molecule technology.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech